IBEX LTD (IBEX) Fundamental Analysis & Valuation

NASDAQ:IBEX • BMG4690M1010

Current stock price

27.7 USD
+0.15 (+0.54%)
At close:
27.7 USD
0 (0%)
After Hours:

This IBEX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. IBEX Profitability Analysis

1.1 Basic Checks

  • In the past year IBEX was profitable.
  • IBEX had a positive operating cash flow in the past year.
  • IBEX had positive earnings in each of the past 5 years.
  • IBEX had a positive operating cash flow in each of the past 5 years.
IBEX Yearly Net Income VS EBIT VS OCF VS FCFIBEX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M

1.2 Ratios

  • The Return On Assets of IBEX (14.98%) is better than 94.32% of its industry peers.
  • The Return On Equity of IBEX (28.69%) is better than 89.77% of its industry peers.
  • IBEX's Return On Invested Capital of 21.96% is amongst the best of the industry. IBEX outperforms 95.45% of its industry peers.
Industry RankSector Rank
ROA 14.98%
ROE 28.69%
ROIC 21.96%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IBEX Yearly ROA, ROE, ROICIBEX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 100

1.3 Margins

  • IBEX's Profit Margin of 7.35% is fine compared to the rest of the industry. IBEX outperforms 68.18% of its industry peers.
  • In the last couple of years the Profit Margin of IBEX has grown nicely.
  • With a decent Operating Margin value of 9.38%, IBEX is doing good in the industry, outperforming 69.32% of the companies in the same industry.
  • In the last couple of years the Operating Margin of IBEX has grown nicely.
  • Looking at the Gross Margin, with a value of 30.36%, IBEX is in line with its industry, outperforming 43.18% of the companies in the same industry.
  • In the last couple of years the Gross Margin of IBEX has remained more or less at the same level.
Industry RankSector Rank
OM 9.38%
PM (TTM) 7.35%
GM 30.36%
OM growth 3Y27.75%
OM growth 5Y12.6%
PM growth 3Y14.82%
PM growth 5Y27.95%
GM growth 3Y0.55%
GM growth 5YN/A
IBEX Yearly Profit, Operating, Gross MarginsIBEX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. IBEX Health Analysis

2.1 Basic Checks

  • IBEX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • IBEX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IBEX Yearly Shares OutstandingIBEX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
IBEX Yearly Total Debt VS Total AssetsIBEX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • IBEX has an Altman-Z score of 4.78. This indicates that IBEX is financially healthy and has little risk of bankruptcy at the moment.
  • IBEX has a Altman-Z score of 4.78. This is amongst the best in the industry. IBEX outperforms 80.68% of its industry peers.
  • IBEX has a debt to FCF ratio of 0.05. This is a very positive value and a sign of high solvency as it would only need 0.05 years to pay back of all of its debts.
  • With an excellent Debt to FCF ratio value of 0.05, IBEX belongs to the best of the industry, outperforming 90.91% of the companies in the same industry.
  • IBEX has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
  • IBEX has a better Debt to Equity ratio (0.00) than 82.95% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.05
Altman-Z 4.78
ROIC/WACC2.29
WACC9.6%
IBEX Yearly LT Debt VS Equity VS FCFIBEX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M

2.3 Liquidity

  • IBEX has a Current Ratio of 1.83. This is a normal value and indicates that IBEX is financially healthy and should not expect problems in meeting its short term obligations.
  • IBEX has a Current ratio (1.83) which is comparable to the rest of the industry.
  • IBEX has a Quick Ratio of 1.83. This is a normal value and indicates that IBEX is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Quick ratio value of 1.83, IBEX perfoms like the industry average, outperforming 55.68% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.83
Quick Ratio 1.83
IBEX Yearly Current Assets VS Current LiabilitesIBEX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. IBEX Growth Analysis

3.1 Past

  • IBEX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.77%, which is quite impressive.
  • IBEX shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 41.04% yearly.
  • IBEX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 15.63%.
  • IBEX shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.62% yearly.
EPS 1Y (TTM)44.77%
EPS 3Y28.16%
EPS 5Y41.04%
EPS Q2Q%47.46%
Revenue 1Y (TTM)15.63%
Revenue growth 3Y4.24%
Revenue growth 5Y6.62%
Sales Q2Q%16.73%

3.2 Future

  • Based on estimates for the next years, IBEX will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.88% on average per year.
  • Based on estimates for the next years, IBEX will show a quite strong growth in Revenue. The Revenue will grow by 9.67% on average per year.
EPS Next Y23.31%
EPS Next 2Y13.88%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year13.82%
Revenue Next 2Y9.67%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IBEX Yearly Revenue VS EstimatesIBEX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M
IBEX Yearly EPS VS EstimatesIBEX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

8

4. IBEX Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 8.01, the valuation of IBEX can be described as very reasonable.
  • 90.91% of the companies in the same industry are more expensive than IBEX, based on the Price/Earnings ratio.
  • Compared to an average S&P500 Price/Earnings ratio of 25.60, IBEX is valued rather cheaply.
  • With a Price/Forward Earnings ratio of 7.63, the valuation of IBEX can be described as very cheap.
  • Based on the Price/Forward Earnings ratio, IBEX is valued cheaper than 86.36% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 22.84, IBEX is valued rather cheaply.
Industry RankSector Rank
PE 8.01
Fwd PE 7.63
IBEX Price Earnings VS Forward Price EarningsIBEX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • 93.18% of the companies in the same industry are more expensive than IBEX, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, IBEX is valued a bit cheaper than the industry average as 72.73% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 12.69
EV/EBITDA 4.81
IBEX Per share dataIBEX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

  • IBEX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of IBEX may justify a higher PE ratio.
  • IBEX's earnings are expected to grow with 13.88% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.34
PEG (5Y)0.2
EPS Next 2Y13.88%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IBEX Dividend Analysis

5.1 Amount

  • IBEX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IBEX Fundamentals: All Metrics, Ratios and Statistics

IBEX LTD

NASDAQ:IBEX (4/2/2026, 8:00:02 PM)

After market: 27.7 0 (0%)

27.7

+0.15 (+0.54%)

Chartmill FA Rating
GICS IndustryGroupSoftware & Services
GICS IndustryIT Services
Earnings (Last)02-05
Earnings (Next)05-06
Inst Owners96.38%
Inst Owner Change3.63%
Ins Owners6.19%
Ins Owner Change16.7%
Market Cap371.46M
Revenue(TTM)603.27M
Net Income(TTM)44.32M
Analysts45.71
Price Target41.82 (50.97%)
Short Float %1.72%
Short Ratio1.39
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.35%
Min EPS beat(2)8.65%
Max EPS beat(2)20.05%
EPS beat(4)4
Avg EPS beat(4)15.36%
Min EPS beat(4)8.65%
Max EPS beat(4)21.85%
EPS beat(8)8
Avg EPS beat(8)15.45%
EPS beat(12)10
Avg EPS beat(12)11.12%
EPS beat(16)13
Avg EPS beat(16)15.27%
Revenue beat(2)2
Avg Revenue beat(2)3.02%
Min Revenue beat(2)2.5%
Max Revenue beat(2)3.54%
Revenue beat(4)4
Avg Revenue beat(4)4.92%
Min Revenue beat(4)2.5%
Max Revenue beat(4)8.52%
Revenue beat(8)6
Avg Revenue beat(8)2.69%
Revenue beat(12)6
Avg Revenue beat(12)0.39%
Revenue beat(16)7
Avg Revenue beat(16)-0.19%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-3.93%
EPS NQ rev (3m)-6.04%
EPS NY rev (1m)0.3%
EPS NY rev (3m)0.3%
Revenue NQ rev (1m)0.45%
Revenue NQ rev (3m)1.36%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.89%
Valuation
Industry RankSector Rank
PE 8.01
Fwd PE 7.63
P/S 0.62
P/FCF 12.69
P/OCF 6.29
P/B 2.4
P/tB 2.6
EV/EBITDA 4.81
EPS(TTM)3.46
EY12.49%
EPS(NY)3.63
Fwd EY13.11%
FCF(TTM)2.18
FCFY7.88%
OCF(TTM)4.41
OCFY15.9%
SpS44.99
BVpS11.52
TBVpS10.64
PEG (NY)0.34
PEG (5Y)0.2
Graham Number29.95
Profitability
Industry RankSector Rank
ROA 14.98%
ROE 28.69%
ROCE 27.05%
ROIC 21.96%
ROICexc 23.71%
ROICexgc 25.25%
OM 9.38%
PM (TTM) 7.35%
GM 30.36%
FCFM 4.85%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y27.75%
OM growth 5Y12.6%
PM growth 3Y14.82%
PM growth 5Y27.95%
GM growth 3Y0.55%
GM growth 5YN/A
F-Score8
Asset Turnover2.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.05
Debt/EBITDA 0.01
Cap/Depr 168.3%
Cap/Sales 4.94%
Interest Coverage 42.98
Cash Conversion 79.5%
Profit Quality 66.06%
Current Ratio 1.83
Quick Ratio 1.83
Altman-Z 4.78
F-Score8
WACC9.6%
ROIC/WACC2.29
Cap/Depr(3y)83.97%
Cap/Depr(5y)108.52%
Cap/Sales(3y)2.89%
Cap/Sales(5y)3.72%
Profit Quality(3y)75.63%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.77%
EPS 3Y28.16%
EPS 5Y41.04%
EPS Q2Q%47.46%
EPS Next Y23.31%
EPS Next 2Y13.88%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)15.63%
Revenue growth 3Y4.24%
Revenue growth 5Y6.62%
Sales Q2Q%16.73%
Revenue Next Year13.82%
Revenue Next 2Y9.67%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y17.68%
EBIT growth 3Y33.16%
EBIT growth 5Y20.06%
EBIT Next Year68.46%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y50.53%
FCF growth 3Y24.66%
FCF growth 5Y-10.09%
OCF growth 1Y85.57%
OCF growth 3Y4.51%
OCF growth 5Y-2.46%

IBEX LTD / IBEX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for IBEX LTD?

ChartMill assigns a fundamental rating of 7 / 10 to IBEX.


What is the valuation status for IBEX stock?

ChartMill assigns a valuation rating of 8 / 10 to IBEX LTD (IBEX). This can be considered as Undervalued.


How profitable is IBEX LTD (IBEX) stock?

IBEX LTD (IBEX) has a profitability rating of 7 / 10.


Can you provide the financial health for IBEX stock?

The financial health rating of IBEX LTD (IBEX) is 7 / 10.


Is the dividend of IBEX LTD sustainable?

The dividend rating of IBEX LTD (IBEX) is 0 / 10 and the dividend payout ratio is 0%.